Published in Gene Therapy Weekly, November 13th, 1995
One strategy for achieving efficient delivery of therapeutic prodrug-activating genes is the stereotactic implantation of fibroblasts that express a foreign gene as well as producing a retroviral vector that bears that gene. Another method involves the grafting of genetically engineered fibroblasts that produce the foreign gene product, but do not replicate in the host.
In order to determine the extent of the differences between the two protocols, T. Tamiya et al....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.